Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | ERCC1 | P07992 | 2/20 | 0.39 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | F12 | P00748 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 2/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38361 | 0.91 | ACHE (0.48) | ERCC1ERCC4ACHEBACE1MEN1 | |
| SCHEMBL43467 | 0.90 | TRPV1 (0.48) | ACHEBACE1F12MEN1KMT2A | |
| SCHEMBL38457 | 0.83 | ERCC1 (0.45) | ERCC1ERCC4ACHEBACE1F12 | |
| SCHEMBL42916 | 0.81 | ACHE (0.56) | ACHEBACE1TRPV1RAB9ANPC1 | |
| SCHEMBL43329 | 0.81 | NPC1 (0.65) | ACHEBACE1MAPTMEN1KMT2A | |
| SCHEMBL38831 | 0.78 | ERCC1 (0.42) | ERCC1ERCC4ACHEBACE1MEN1 | |
| SCHEMBL38357 | 0.78 | ERCC1 (0.42) | ERCC1ERCC4ACHEBACE1MEN1 | |
| SCHEMBL38362 | 0.75 | ACHE (0.49) | ERCC1ERCC4ACHEBACE1MEN1 | |
| SCHEMBL38814 | 0.75 | ERCC1 (0.43) | ERCC1ERCC4ACHEBACE1MEN1 | |
| SCHEMBL38815 | 0.75 | ERCC1 (0.43) | ERCC1ERCC4ACHEBACE1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367835-B2 | Cyclic amine-1-carboxylic acid ester derivative and pharmaceutical composition containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120028937-A1 | CYCLIC AMINE-1-CARBOXYLIC ACID ESTER DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028937-A1 | CYCLIC AMINE-1-CARBOXYLIC ACID ESTER DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | HRH3, ARG1, CNR1 | CES2 1581/4885ERCC1 3649/4885ERCC4 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.